Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-24T12:06:49.570Z Has data issue: false hasContentIssue false
  • English
  • Français

Mechanisms of Action of Atypical Antipsychotics

Published online by Cambridge University Press:  07 November 2014

Fernando Cañas
Get access Rights & Permissions [Opens in a new window]

Abstract

Atypical antipsychotics—clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole—differ from conventional antipsychotics primarily by virtue of their actions at multiple central receptor sites. Each agent has its own unique receptor profile. The discovery of dopaminergic receptor-blocking capabilities of conventionblockingal antipsychotic drugs led to the dopamine hypothesis of schizophrenia. More recently, the role of serotonergic and other receptors in the pathophysiology and symptomology of schizophrenia and schizoaffective disorder has been identified, and the receptor actions of atypical antipsychotics have been linked to both antipsychotic efficacy and the propensity for extrapyramidal symptoms and other adverse effects. Receptor occupancy is directly related to antipsychotic dose, and the nature of the relationship between clinical utility and receptor occupancy is beginning to emerge. As our understanding of this relationship becomes more clear, the mechanism underlying clinical distinctions between agents will be understood.

Type
Academic Supplement
Information
CNS Spectrums , Volume 10 , Issue S10: Recent Advances in the Clinical Use of Atypical Antipsychotics , August 2005 , pp. 5 - 11
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Kapur, S, Seeman, P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25:161–166.Google Scholar
2.Farde, L, Nordstrom, AL, Wiesel, FA, Pauli, S, Halldin, C, Sedvall, G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538–544.CrossRefGoogle ScholarPubMed
3.Meltzer, HY, Matsubara, S, Lee, JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pK1 values. J Pharmacol Exp Ther. 1989;251:238–246.Google Scholar
4.Andreasen, NC, Black, DW. Introductory Textbook of Psychiatry. 3rd ed. Washington, DC: American Psychiatric Press; 2001;204–228.Google Scholar
5.Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184.Google Scholar
6.Ananth, J, Parameswaran, S, Hara, B. Drug therapy in schizophrenia. Curr Pharm Des. 2004;10:2205–2217.Google Scholar
7.Sedvall, G, Farde, L. Chemical brain anatomy in schizophrenia. Lancet. 1995;346:743–749.Google Scholar
8.Seeman, P, Chau-Wong, M, Tedesco, J, Wong, K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A. 1975;72:4376–4380.Google Scholar
9.Sesack, SR, Carr, DB. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav. 2002;77:513–517.CrossRefGoogle ScholarPubMed
10.Nyberg, S, Eriksson, B, Oxenstiema, G, Halldin, C, Farde, L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869–875.Google Scholar
11.Nordstrom, AL, Farde, L, Wiesel, FA, et al.Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227–235.Google Scholar
12.Schlegel, S, Schlosser, R, Hiemke, C, Nickel, O, Bockisch, A, Hahn, K. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology (Berl). 1996;124:285–287.Google Scholar
13.Seeman, P, Kapur, S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA. 2000;97:7673–7675.Google Scholar
14.Seeman, P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol. 1988;8(suppl):S3–S9.Google Scholar
15.Huttunen, M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol. 1995;15(suppl):S4–S10.Google Scholar
16.Bantick, RA, Montgomery, AJ, Bench, CJ, et al.A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol. 2004;18:346–354.Google Scholar
17.Yasuno, F, Suhara, T, Ichimiya, T, Takano, A, Ando, T, Okubo, Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry. 2004;55:439–444.Google Scholar
18.Meltzer, HY, Matsubara, S, Lee, JC. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25:390–392.Google Scholar
19.Goyer, PF, Berridge, MS, Morris, ED, et al.PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med. 1996;37:1122–1127.Google Scholar
20.Meltzer, HY. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bull. 1991;2:263–287.Google Scholar
21.Crook, JM, Tomaskovic-Crook, E, Copolov, DL, Dean, B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry. 2000;48:381–388.Google Scholar
22.Dean, B, Crook, JM, Opeskin, K, Hill, C, Keks, N, Copolov, DL. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry. 1996;1:54–58.Google Scholar
23.Dean, B. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia [Letter]. Neuropsychopharmacology. 2004;29:1583–1584.Google Scholar
24.Kafka, MS, van Kammen, DP. alpha-Adrenergic receptor function in schizophrenia: receptor number, cyclic adenosine monophosphate production, adenylate cyclase activity, and effect of drugs. Arch Gen Psychiatry. 1983;40:264–270.Google Scholar
25.Kalkman, HO, Loetscher, E. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol. 2003;462:33–40.Google Scholar
26.Iversen, PL, Cornish, KG, Iversen, LJ, Mata, JE, Bylund, DB. Bolus intravenous injection of phosphorothioate oligonudeotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists. Toxicol Appl Pharmacol. 1999;160:289–296.Google Scholar
27.Nicholson, AN, Pascoe, PA, Turner, C, et al.Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol. 1991;104:270–276.Google Scholar
28.Hayashi, A, Sonoda, R, Kimura, Y, et al.Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Res. 2004;1011:221–227.Google Scholar
29.Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychophormacology. 2003;28:519–526.Google Scholar
30.Farde, L, Wiesel, FA, Halldin, C, Sedvall, G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45:71–76.Google Scholar
31.Baron, JC, Martinot, JL, Cambon, H, et al.Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychophormacology (Berl). 1989;99:463–472.CrossRefGoogle ScholarPubMed
32.Smith, M, Wolf, AP, Btodie, JD, et al.Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry. 1988;23:653–663.Google Scholar
33.Mamo, D, Kapur, S, Shammi, CM, et al.A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818–825.Google Scholar
34.Leysen, JE, Gommeren, W, Eens, A, de Courcelles, D, Stoof, JC, Janssen, PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247:661–670.Google Scholar
35.Janssen, PA, Niemegeers, CJ, Awouters, F, Schellekens, KH, Megens, AA, Meert, TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988;244:685–693.Google Scholar
36.Bymaster, FP, Calligaro, DO, Falcone, JF, et al.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychophormacology. 1996;14:87–96.Google Scholar
37.Nemeroff, CB, Kinkead, B, Goldstein, J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63(suppl 13):5–11.Google Scholar
38.Hirose, T, Uwahodo, Y, Yamada, S, et al.Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 20O4;18:375–383.Google Scholar
39.Kikuchi, T, Tottori, K, Uwahodo, Y, et al.7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptot antagonistic activity. J Pharmacol Exp Ther. 1995;274:329–336.Google Scholar
40.Carnahan, RM, Lund, BC, Perry, PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy. 2001;21:717–730.Google Scholar
41.Purdon, SE, Jones, BD, Stip, E, et al.Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000;57:249–258.CrossRefGoogle ScholarPubMed
42.Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychophormacology. 1999;20:491–505.CrossRefGoogle ScholarPubMed